PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
| Autor: | H.S.J. Kim, L. Fahham, G. Castilho, A. Buehler, P.A. Dionne |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Postmenopausal women Cost effectiveness business.industry Health Policy Letrozole Public Health Environmental and Occupational Health Ribociclib Palbociclib medicine.disease Metastatic breast cancer Hormone receptor Internal medicine medicine business Human Epidermal Growth Factor Receptor 2 medicine.drug |
| Zdroj: | Value in Health. 22:S466-S467 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2019.09.356 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect